Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis

作     者：Lynne M.Ellison Yangao Man Alexander Stojadinovic Hongwu Xin Itzhak Avital 

作者机构：Bon Secours Cancer Institute Bon Secours Health System Richmond VA 23226 USA Laboratory of Oncology the First People's Hospital of Jingzhou City the First Hospital and Clinical Medical School of Yangtze University Jingzhou 434008 China Laboratory of Oncology Center forMolecular Medicine Medical School Yangtze University Jingzhou 434023 China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2017年第29卷第1期

页      面：86-92页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Cytoreductive surgery hyperthermic intraperitoneal chemotherapy peritoneal carcinomatosis 

摘      要：Although gastric cancer with peritoneal carcinomatosis is associated with poor prognosis and is generally treated with palliative systemic therapy, recent studies have shown that cytoreductive surgery（CRS） and hyperthermic intraperitoneal chemotherapy（HIPEC） may prove to be an efficacious treatment option. In addition to reviewing the natural history of gastric cancer with peritoneal carcinomatosis, this mini-review examines literature on the efficacy of CRS and HIPEC as compared to chemotherapy and surgical options. Both randomized and nonrandomized studies were summarized with the emphasis focused on overall survival. In summary, CRS and HIPEC are indeed a promising treatment option for gastric cancer with peritoneal carcinomatosis and large randomized clinical trials are warranted.